Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia 30303, United States.
ACS Appl Mater Interfaces. 2022 Feb 9;14(5):6331-6342. doi: 10.1021/acsami.1c19192. Epub 2022 Jan 27.
The intranasal (i.n.) route is an ideal vaccination approach for infectious respiratory diseases like influenza. Polycationic polyethylenimine (PEI) could form nanoscale complexes with negatively charged viral glycoproteins. Here we fabricated PEI-hemagglutinin (HA) and PEI-HA/CpG nanoparticles and investigated their immune responses and protective efficacies with an i.n. vaccination regimen in mice. Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, providing heterologous cross-protection. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups. In contrast to the Th2-biased, IgG1-dominant antibody response generated by PEI-HA nanoparticles, PEI-HA/CpG nanoparticles generated more robust and balanced IgG1/IgG2a antibody responses with augmented neutralization activity and Fc-mediated antibody-dependent cellular cytotoxicity (ADCC). PEI-HA/CpG nanoparticles also induced enhanced local and systemic cellular immune responses. These immune responses did not decay over six months of observation postimmunization. PEI and CpG synergized these comprehensive immune responses. Thus, the PEI-HA/CpG nanoparticle is a potential cross-protective influenza vaccine candidate. Polycationic PEI nanoplatforms merit future development into mucosal vaccine systems.
鼻腔(i.n.)途径是流感等传染性呼吸道疾病的理想疫苗接种方法。多阳离子聚乙烯亚胺(PEI)可以与带负电荷的病毒糖蛋白形成纳米级复合物。在这里,我们制备了 PEI-血凝素(HA)和 PEI-HA/CpG 纳米颗粒,并通过鼻腔免疫方案在小鼠中研究了它们的免疫反应和保护效力。我们的结果表明,纳米颗粒显著增强了 HA 的免疫原性,提供了异源交叉保护。保守的 HA 茎区在纳米颗粒免疫组中诱导了大量抗体。与 PEI-HA 纳米颗粒产生的偏向 Th2、以 IgG1 为主的抗体反应相反,PEI-HA/CpG 纳米颗粒产生了更强大和平衡的 IgG1/IgG2a 抗体反应,增强了中和活性和 Fc 介导的抗体依赖性细胞细胞毒性(ADCC)。PEI-HA/CpG 纳米颗粒还诱导了增强的局部和全身细胞免疫反应。这些免疫反应在免疫后六个月的观察期内没有衰退。PEI 和 CpG 协同增强了这些全面的免疫反应。因此,PEI-HA/CpG 纳米颗粒是一种有潜力的具有交叉保护作用的流感疫苗候选物。阳离子 PEI 纳米平台值得进一步开发为粘膜疫苗系统。